Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up
| Autor: | Xueyan Liao, Teng Huang, Youping Liu, Yanping Li, Qiong Shou, Minghuan Zheng, Rong-Cheng Li, Yuqin Liao |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male China medicine.medical_specialty Adolescent Alphapapillomavirus Antibodies Viral Serogroup Persistence (computer science) Young Adult 03 medical and health sciences Immunogenicity Vaccine 0302 clinical medicine Immune system Seroepidemiologic Studies Internal medicine Humans Medicine Papillomavirus Vaccines 030212 general & internal medicine Child General Veterinary General Immunology and Microbiology Hpv types biology business.industry Extension study Immunogenicity Papillomavirus Infections Vaccination Public Health Environmental and Occupational Health Middle Aged Regimen Infectious Diseases Immunoglobulin G 030220 oncology & carcinogenesis biology.protein Molecular Medicine Female Antibody business Follow-Up Studies |
| Zdroj: | Vaccine. 36:1368-1374 |
| ISSN: | 0264-410X |
| Popis: | Background This was an extension study of a randomized, double-blind, placebo-controlled immunogenicity and safety study of the quadrivalent human papillomavirus (qHPV) (HPV 6, 11, 16, and 18) vaccine conducted in Chinese female subjects aged 9–45 years and male subjects aged 9–15 years. To investigate the persistence of anti-HPV 6, -11, -16, and -18 responses among Chinese subjects, subjects enrolled in the base study were followed up at around month 42 (approximately 3.5 years after vaccination). Methods Among 600 subjects enrolled in the base study, a total of 468 subjects consented for participation in the extension study. Anti-HPV 6, -11, -16, and -18 antibodies were detected by the competitive Luminex immunoassay (cLIA) and total IgG Luminex immunoassay (IgG LIA). Results Among the female subjects who received the qHPV vaccine, the proportions of subjects remained seropositive were high with both the cLIA and IgG LIA for HPV type 6, 11, and 16 through approximately 42 months following the first dose vaccination. For HPV 18, the seropositivity rate remained high as 82.0% with the IgG LIA, while it decreased to 53.6% with the cLIA, which was similar to the findings observed in other studies. The seropositivity rates remained high at month 42 for all qHPV types with both the cLIA and IgG LIA among the male subjects. Conclusions Administration of a 3-dose regimen of qHPV vaccine induces durable anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 responses among Chinese subjects for at least 3.5 years after vaccination. ClinicalTrials.gov registry: NCT01427777 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect